Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02142543
Other study ID # BCDOrtho1
Secondary ID 2011-23-BCD
Status Completed
Phase Phase 0
First received April 24, 2014
Last updated June 4, 2014
Start date March 2012
Est. completion date December 2012

Study information

Verified date June 2014
Source Texas A&M University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, blinded, placebo-controlled, crossover clinical trial to evaluate the efficacy of 2-DeNT oral topical powder in the treatment of recurrent aphthous stomatitis (RAS). To be included in the study, subjects must have had minor RAS ulcers of less than 48 hours duration. It was randomly determined which powder was used first; all subjects used both the 2-DeNT powder and the placebo powder. Subjects applied the powder twice daily and maintained a daily log recording the size of the ulcer, its erythema score, and their level of pain. The subjects continued applying the 2-DeNT powder until the ulcer was resolved.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 12 Years to 55 Years
Eligibility Inclusion Criteria:

- a history of minor recurrent aphthous stomatitis (RAS) lesions occurring at least 3-4 time/ year, and usually requiring 5 or more days to resolve

- presence of an active ulcer of less than 48 hours duration on either the buccal or labial mucosa (making them more easily accessible for powder application)

- willing and able to give informed consent

Exclusion Criteria:

- pregnant or lactating

- if ulcers were manifestations of a systemic disease process such as ulcerative colitis, Crohn's disease, Behcet's syndrome, or anemia;

- concurrent clinical conditions that could either pose a health risk to the patient by being involved in the study or potentially influence the outcome of the study

- hypersensitivity to dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, karaya gum, or zinc oxide

- having used corticosteroids, oral retinoids, or other immunomodulatory agents within one month of participation in the study; non-steroidal anti-inflammatory agents (e.g., aspirin, ibuprofen, etc.), acetaminophen, or oral antihistamines chronically within one month of participation in the study or any use within five days of participation in the study; topical medication (including steroids, retinoids, and anti-microbial drugs) within two weeks of participation in the study, systemic antibiotics within two weeks of participation in the study; any preparation or medication (OTC or prescription) applied to the ulcer within 48 hours of participation in the study

- history of drug or alcohol abuse

- having had any dental work within 2 weeks of study entry

- having had any orthodontic or oral appliances (that could cause oral trauma) within 1 cm of the ulcer or any recollection of trauma in the area of the ulcer

- participating in any other study involving investigational or marketed products within 1 month of study entry or plans to participate in such an investigation during this study.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
2-DeNT powder
powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
Placebo Comparator


Locations

Country Name City State
United States Texas A&M Baylor College of Dentisry Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
Texas A&M University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Pain The perceived level of pain or discomfort was noted by the subject using a 10 cm visual analogue scale (VAS) with anchors of "no pain" and "worst pain ever" From time of randomization until ulcer was healed, an expected average of 3 to 5 days No
Primary Ulcer size Size was measured from the outside edge of the white border to the outside edge of the opposite white border. If the ulcer was oval in shape, its longest dimension was measured. From time of randomization until ulcer was healed, an expected average of 3 to 5 days No
Secondary Erythema Erythema levels were recorded on a scale of 0 to 4 (0= no redness, 1= faint redness, 2= light red/pink, 3= moderate redness, 4= severe redness) using a guide that provided both picture and word descriptions of the degree of redness associated with each number on the scale From time of randomization until ulcer was healed, an expected average of 3 to 5 days No